290 related articles for article (PubMed ID: 19560743)
1. Novel drug delivery strategies in neuro-oncology.
Bidros DS; Vogelbaum MA
Neurotherapeutics; 2009 Jul; 6(3):539-46. PubMed ID: 19560743
[TBL] [Abstract][Full Text] [Related]
2. Convection-enhanced and local delivery of targeted cytotoxins in the treatment of malignant gliomas.
Muro K; Das S; Raizer JJ
Technol Cancer Res Treat; 2006 Jun; 5(3):201-13. PubMed ID: 16700617
[TBL] [Abstract][Full Text] [Related]
3. Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors.
Ferguson S; Lesniak MS
Curr Drug Deliv; 2007 Apr; 4(2):169-80. PubMed ID: 17456036
[TBL] [Abstract][Full Text] [Related]
4. Convection-enhanced delivery of immunotoxins and radioisotopes for treatment of malignant gliomas.
Vandergrift WA; Patel SJ; Nicholas JS; Varma AK
Neurosurg Focus; 2006 Apr; 20(4):E13. PubMed ID: 16709018
[TBL] [Abstract][Full Text] [Related]
5. Imaging of convection enhanced delivery of toxins in humans.
Mehta AI; Choi BD; Raghavan R; Brady M; Friedman AH; Bigner DD; Pastan I; Sampson JH
Toxins (Basel); 2011 Mar; 3(3):201-6. PubMed ID: 22069706
[TBL] [Abstract][Full Text] [Related]
6. Convection-enhanced delivery in clinical trials.
Hall WA; Rustamzadeh E; Asher AL
Neurosurg Focus; 2003 Feb; 14(2):e2. PubMed ID: 15727423
[TBL] [Abstract][Full Text] [Related]
7. Future of convection-enhanced delivery in the treatment of brain tumors.
Bidros DS; Liu JK; Vogelbaum MA
Future Oncol; 2010 Jan; 6(1):117-25. PubMed ID: 20021213
[TBL] [Abstract][Full Text] [Related]
8. Current status of local therapy in malignant gliomas--a clinical review of three selected approaches.
Juratli TA; Schackert G; Krex D
Pharmacol Ther; 2013 Sep; 139(3):341-58. PubMed ID: 23694764
[TBL] [Abstract][Full Text] [Related]
9. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous.
Drapeau A; Fortin D
Curr Cancer Drug Targets; 2015; 15(9):752-68. PubMed ID: 26077730
[TBL] [Abstract][Full Text] [Related]
11. Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies.
Kunwar S; Chang SM; Prados MD; Berger MS; Sampson JH; Croteau D; Sherman JW; Grahn AY; Shu VS; Dul JL; Husain SR; Joshi BH; Pedain C; Puri RK
Neurosurg Focus; 2006 Apr; 20(4):E15. PubMed ID: 16709020
[TBL] [Abstract][Full Text] [Related]
12. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
Karim R; Palazzo C; Evrard B; Piel G
J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752
[TBL] [Abstract][Full Text] [Related]
13. Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium.
Doolittle ND; Anderson CP; Bleyer WA; Cairncross JG; Cloughesy T; Eck SL; Guastadisegni P; Hall WA; Muldoon LL; Patel SJ; Peereboom D; Siegal T; Neuwelt EA
Neuro Oncol; 2001 Jan; 3(1):46-54. PubMed ID: 11305417
[TBL] [Abstract][Full Text] [Related]
14. A novel bispecific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells to target blood vessels and vasculogenic mimicry of malignant gliomas.
Zhang Y; Sun X; Huang M; Ke Y; Wang J; Liu X
Drug Des Devel Ther; 2015; 9():2947-59. PubMed ID: 26089644
[TBL] [Abstract][Full Text] [Related]
15. Novel delivery strategies for glioblastoma.
Zhou J; Atsina KB; Himes BT; Strohbehn GW; Saltzman WM
Cancer J; 2012; 18(1):89-99. PubMed ID: 22290262
[TBL] [Abstract][Full Text] [Related]
16. Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning.
Sampson JH; Brady ML; Petry NA; Croteau D; Friedman AH; Friedman HS; Wong T; Bigner DD; Pastan I; Puri RK; Pedain C
Neurosurgery; 2007 Feb; 60(2 Suppl 1):ONS89-98; discussion ONS98-9. PubMed ID: 17297371
[TBL] [Abstract][Full Text] [Related]
17. Drug delivery strategies for the treatment of malignant gliomas.
Allhenn D; Boushehri MA; Lamprecht A
Int J Pharm; 2012 Oct; 436(1-2):299-310. PubMed ID: 22721856
[TBL] [Abstract][Full Text] [Related]
18. Delivering Therapeutics to Glioblastoma: Overcoming Biological Constraints.
Mathew EN; Berry BC; Yang HW; Carroll RS; Johnson MD
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163633
[TBL] [Abstract][Full Text] [Related]
19. Drug delivery strategies to enhance the permeability of the blood-brain barrier for treatment of glioma.
Zhang F; Xu CL; Liu CM
Drug Des Devel Ther; 2015; 9():2089-100. PubMed ID: 25926719
[TBL] [Abstract][Full Text] [Related]
20. Malignant Intracranial High Grade Glioma and Current Treatment Strategy.
Zhang X; Zhang W; Mao XG; Cao WD; Zhen HN; Hu SJ
Curr Cancer Drug Targets; 2019; 19(2):101-108. PubMed ID: 29848277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
